Eli Lilly has announced that it is halting clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for treatment of patients with schizophrenia. The decision was made after a recently conducted independent futility analysis concluded that HBBN, the second of Lilly’s two pivotal studies, was unlikely to be positive in its primary efficacy endpoint if enrolled to completion. The decision was not based on safety concerns. Additionally, the recently completed phase 2 study, HBCO, which investigated pomaglumetad methionil as an adjunctive treatment with atypical antipsychotics, did not meet its primary endpoint.
Lilly said it is contacting study investigators to outline specific actions related to the closeout of each ongoing study and will work with investigators to ensure appropriate transition of study participants to clinical care outside of the trials.